Lipitor Gains Prevention Indication For Patients With Normal Cholesterol
This article was originally published in Pharmaceutical Approvals Monthly
Pfizer’s Lipitor approval for prevention of cardiovascular disease in patients with normal to mildly elevated cholesterol levels will give the firm a new indication to promote as the Merck/Schering joint venture rolls out its new combo cholesterol therapy Vytorin.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class